From NASDAQ.:

Precision BioSciences (DTIL) shares surged 20.4% to close at $16, supported by high volume. This rise is attributed to positive investor sentiment on the company’s gene editing program PBGENE-HBV, in pre-clinical stage. The FDA and other agencies provided clarity on its clinical strategy, aiming for phase I studies in 2024.

Analysts expect Precision BioSciences to post quarterly earnings of $3 per share, a 138.4% increase year-over-year, with revenues reaching $28.5 million, up 168.9%. While EPS estimates remain steady, keep an eye on the stock for potential strength. The company currently holds a Zacks Rank #3 in the Medical – Biomedical and Genetics industry.

Cue Biopharma, Inc. closed 5.5% higher at $2.12 in the last trading session. Analysts project a -$0.29 EPS for the upcoming report, a 21.6% increase from last year. With a Zacks Rank of #3, Cue Biopharma maintains consistency in estimates. See Zacks’s Top 10 Stocks for 2024, handpicked for potential growth opportunities.



Read more at NASDAQ.: Strength Seen in Precision BioSciences (DTIL): Can Its 20.4% Jump Turn into More Strength?